Drug Profile
TAK 783
Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Th1 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
- 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in Japan (PO)
- 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)